Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP1 | O94782 | 2/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | JAK3 | P52333 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 8/20 | 0.37 |
| ▸ | TDO2 | P48775 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.34 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2817792 | 0.89 | CYP11B2 (0.39) | CYP11B2KDM4EALDH1A1LMNAPOLB | |
| SCHEMBL2818099 | 0.89 | CYP11B2 (0.39) | CYP11B2KDM4EALDH1A1LMNAPOLB | |
| SCHEMBL2817793 | 0.89 | CYP11B2 (0.39) | CYP11B2KDM4EALDH1A1LMNAPOLB | |
| SCHEMBL9673472 | 0.88 | MAPK1 (0.40) | USP1CYP11B2JAK2JAK3POLB | |
| SCHEMBL9674071 | 0.83 | OPRL1 (0.39) | USP1CYP11B2JAK2JAK3ALDH1A1 | |
| SCHEMBL2817728 | 0.81 | CYP11B2 (0.43) | CYP11B2IDO1TDO2MAPK1 | |
| SCHEMBL2820348 | 0.80 | CYP11B2 (0.41) | CYP11B2IDO1TDO2 | |
| SCHEMBL2820351 | 0.80 | CYP11B2 (0.41) | CYP11B2IDO1TDO2 | |
| SCHEMBL2820997 | 0.80 | CYP11B2 (0.41) | CYP11B2IDO1TDO2 | |
| SCHEMBL2819795 | 0.79 | CYP11B2 (0.45) | CYP11B2IDO1TDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8436035-B2 | Organic compounds | NOVARTIS AG (CH) | 2013-05-07 | — | — | US | disclosed |
| US-8436035-B2 | Organic compounds | NOVARTIS AG (CH) | 2013-05-07 | — | — | US | disclosed |
| EP-2213668-A2 | Imidazoles as aldosterone synthase inhibitors | Novartis AG (CH) | 2010-08-04 | — | — | EP | disclosed |
| US-20100048562-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-02-25 | — | — | US | disclosed |
| US-20100048562-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-02-25 | — | — | US | disclosed |
| US-20100048562-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-02-25 | — | — | US | disclosed |
| WO-2008076336-A2 | IMIDAZOLES AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048562-A1 | ORGANIC COMPOUNDS | CYP11B1, HSD11B1, CYP17A1 | USP1 2488/4885CYP11B2 6/4885JAK2 1800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.